[{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-002","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication in PNAS Unveils Molecular Pathway Required for Influenza Virus Replication with Large Potential as an Antiviral Drug Target","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-002","moa":"MEK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ATR-002","moa":"MEK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Biocure Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"zapnometinib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atriva Therapeutics \/ Biocure Technology","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."}]

Find Clinical Drug Pipeline Developments & Deals by Atriva Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Through the acquisition, Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses, including ATR-002 (zapnometinib), a first-in-class,...

                          Product Name : ATR-002

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 18, 2023

                          Lead Product(s) : zapnometinib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Biocure Technology

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support ...

                          Product Name : ATR-002

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 13, 2021

                          Lead Product(s) : zapnometinib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : ATR-002 is an oral small molecule, in a dose escalation study demonstrated excellent safety and tolerability and the observed pharmacokinetic profile supports the intended once-daily regime for the upcomi...

                          Product Name : ATR-002

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 30, 2020

                          Lead Product(s) : zapnometinib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Atriva’s lead product ATR-002 candidate is the only host-targeted antiviral specifically developed to treat respiratory infections with RNA viruses, such as influenza virus and the novel SARS-CoV-2.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 28, 2020

                          Lead Product(s) : zapnometinib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank